Zacks: Brokerages Anticipate Mylan NV (NASDAQ:MYL) to Announce $1.29 Earnings Per Share

Wall Street analysts expect that Mylan NV (NASDAQ:MYL) will announce earnings per share (EPS) of $1.29 for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Mylan’s earnings, with the highest EPS estimate coming in at $1.32 and the lowest estimate coming in at $1.27. Mylan posted earnings per share of $1.30 during the same quarter last year, which indicates a negative year-over-year growth rate of 0.8%. The company is scheduled to report its next quarterly earnings results on Tuesday, February 25th.

On average, analysts expect that Mylan will report full-year earnings of $4.31 per share for the current fiscal year, with EPS estimates ranging from $4.20 to $4.40. For the next financial year, analysts anticipate that the business will report earnings of $4.47 per share, with EPS estimates ranging from $4.30 to $4.67. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Mylan.

Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.03. The firm had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3.01 billion. Mylan had a net margin of 0.42% and a return on equity of 18.80%. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.25 earnings per share.

Several research firms recently issued reports on MYL. ValuEngine raised shares of Mylan from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. BidaskClub raised shares of Mylan from a “sell” rating to a “hold” rating in a report on Thursday, November 28th. SunTrust Banks increased their price target on shares of Mylan from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, September 12th. Cfra raised shares of Mylan to a “hold” rating in a report on Wednesday, November 27th. Finally, Morgan Stanley cut shares of Mylan from an “overweight” rating to an “equal” rating and cut their price target for the stock from $25.00 to $18.00 in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $27.97.

In related news, insider Goulds Bruce 8,000,000 shares of the stock in a transaction dated Friday, November 8th. 0.81% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Mylan by 19.2% during the second quarter. Vanguard Group Inc. now owns 56,048,375 shares of the company’s stock worth $1,067,160,000 after acquiring an additional 9,026,215 shares during the last quarter. Phoenix Holdings Ltd. acquired a new stake in Mylan during the third quarter worth approximately $56,507,000. Banco Santander S.A. acquired a new stake in Mylan during the third quarter worth approximately $55,384,000. Nuveen Asset Management LLC boosted its position in Mylan by 824.3% during the second quarter. Nuveen Asset Management LLC now owns 1,681,501 shares of the company’s stock worth $31,898,000 after acquiring an additional 1,499,579 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Mylan by 312.6% during the second quarter. Point72 Asset Management L.P. now owns 1,769,543 shares of the company’s stock worth $33,692,000 after acquiring an additional 1,340,643 shares during the last quarter. Institutional investors and hedge funds own 86.54% of the company’s stock.

NASDAQ MYL traded down $0.54 during trading hours on Friday, hitting $19.14. 4,883,049 shares of the stock were exchanged, compared to its average volume of 5,586,987. The company has a market cap of $9.71 billion, a price-to-earnings ratio of 4.18, a price-to-earnings-growth ratio of 1.01 and a beta of 1.71. Mylan has a 12-month low of $16.63 and a 12-month high of $32.23. The stock has a 50-day moving average of $18.41 and a 200 day moving average of $18.86. The company has a quick ratio of 0.84, a current ratio of 1.43 and a debt-to-equity ratio of 1.17.

About Mylan

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Read More: The Discount Rate – What You Need to Know

Get a free copy of the Zacks research report on Mylan (MYL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.